{"nct_id":"NCT01714739","title":"A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors","status":"COMPLETED","status_verified_date":"2023-01","start_date":"2012-10-07","start_date_type":"ACTUAL","primary_completion_date":"2019-12-13","primary_completion_date_type":"ACTUAL","completion_date":"2019-12-13","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["BMY"]}